Anti-B7H3-Antikörper zur Herstellung von Antikörper-Wirkstoff-Konjugaten (adcs) von Ksp-Inhibitoren

Details

Veröffentlichungs-Nr.

EP4725560

Anmeldetag

20. Juni 2016

Veröffentlichung

15. April 2026

Rechtsraum

EP

IPC

A61P43/00, C07K16/28A61P43/00(DAIICHI SANKYO CO LTD et al.)(TAKAHASHI SHU et al.)(JOHNSON LESLIE S et al.)

Abstract

The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

Anmelder

Firma

Bayer Pharma Aktiengesellschaft

Land

🇩🇪 Deutschland

Fachgebiete